抗ICAM-1单克隆抗体抑制大鼠角膜移植排斥反应的实验研究

目的 :探讨应用抗细胞间粘附分子 (Intercellularadhesionmolecule 1,ICAM 1)单克隆抗体中和治疗大鼠角膜移植排斥反应的效果。方法 :应用两种主要组织相容抗原完全不同的大鼠Louis和RCS鼠 ,建立近交系大鼠穿透性角膜移植动物模型 ,分三组给药 ,其分别是抗细胞间粘附分子单克隆抗体组 (抗ICAM 1抗体组 )、生理盐水组和环胞霉素A(CsA)组。观察角膜移植排斥发生的时间及治疗效果。标本作HE染色及免疫组化染色 ,观察免疫排斥反应的程度及炎症程度。结果 :三组角膜植片平均存活时间为 :生理盐水组角膜移植排斥反应平均发生时间为术后 12 .1天 ,CsA组为18.3天 ,抗ICAM 1抗体组为 2 0 .2天。HE染色显示抗ICAM 1抗体组及CsA组的炎症反应较生理盐水组明显减轻 ,免疫组化染色显示抗ICAM 1抗体组和CsA组的ICAM 1表达较生理盐水组明显减少。结论 :抗ICAM 1单克隆抗体中和治疗可减少移植角膜ICAM 1表达及免疫炎性细胞的浸润 ,减轻角膜移植免疫排斥反应 ,延长移植片的存活时间 ,是一种有效的新型免疫抑制剂

Experimental study in the use of ICAM-1 monoclonal antibody to inhibit immunity rejection in rat corneal transplants

Objective:To investigate the results of using the monoclonal antibody of intercellular adhesion molecule 1(ICAM 1) in neutralization therapy for inhibiting immunity rejection in rat corneal transplants.Methods:This research establishes a model for corneal penetrating transplants in inbred rat lines,a total of 30 rats. Two different kinds of inbred rat lines were used,such as louis rats and RCS rats. Those rats were randomly divided into three groups,the ICAM 1 monoclonal antibody group,the saline group and the CsA group. The time when corneal transplant immunity rejection occurred and the effectiveness of the therapy were recorded. Tissues of corneal transplants from the three groups of rats were cut in consecutive cryosection,and treated with SABC immunohistochemistry and HE staining. The relationship between the intensity of immunity rejection and the severity of inflammation was monitored.Results:The average survival period for corneal transplants in the three groups,defined by corneal transplant immunity rejection,was 12.1 days postsurgery for the saline group,18.3 days postsurgery for the CsA group and 20.2 days postsurgery for the ICAM 1 monoclonal antibody group. The sections with HE staining revealed that the severity of inflammation in the ICAM 1 monoclonal antibody group and CsA group was reduced compared with that of the saline group. SABC immunohistochemistry staining revealed that the intensity of ICAM 1 expression in the corneal transplants of the ICAM 1 monoclonal antibody group and CsA group was lower than that for the saline group.Conclusion:The monoclonal antibody of ICAM 1 neutralization therapy method can decrease the intensity of ICAM 1 expression and the infiltration of immune inflammation cells in corneal transplants,can relieve the severity of immunity rejection in corneal transplants,and can lengthen the survival period for corneal transplants. ICAM 1 monoclonal antibody is an effective,new immunosuppressive agent.